Original Article
Risk of Thrombolytic Therapy for Acute Ischemic Stroke in Patients With Current Malignancy

https://doi.org/10.1016/j.jstrokecerebrovasdis.2009.10.010Get rights and content

Little is known about the risk of thrombolysis in patients with malignancy, because these patients have been excluded from most clinical trials. We reviewed our acute ischemic stroke (AIS) database for clinical outcomes and complications in patients with current malignancy (CM) who received thrombolytic therapy. Consecutive AIS patients receiving thrombolysis between January 2003 and December 2006 were retrospectively abstracted in accordance with the American Stroke Association's Get With the Guidelines–Stroke definitions and charts were reviewed for history of malignancy. Patients with brain metastases did not receive tissue plasminogen activator (tPA). Stepwise logistic regression was used to identify independent predictors of in-hospital mortality. Of 308 AIS patients treated with thrombolytic therapy, 210 (68%) received intravenous (IV) tPA only, 41 (13%) received IV tPA plus intra-arterial therapy (IAT), and 57 (18%) received IAT only. Eighteen patients (5.8%) had a CM, and 26 patients (8.4%) had a remote history of malignancy. Patients with CM had a higher in-hospital mortality (38.9% vs 19.7 %; P = .05) and were more likely to have died due to worsening medical comorbidity (71.4% vs 9.6%; P < .001). The rate of symptomatic intracranial hemorrhage (ICH) was similar in the 2 groups (5.6% vs 2.7%; P = .47). In multivariate analysis, the only independent predictors of mortality were National Institutes of Health Stroke Scale score, history of hypertension, and smoking. CM was not independently associated with increased in-hospital mortality following thrombolysis. Mortality was attributable largely to medical comorbidities, not to symptomatic ICH. Our data suggest that thrombolysis may be a reasonable option for patients with malignancy who have acceptable medical comorbidities and performance status. Further research is warranted.

Section snippets

Patient Selection

This study was a retrospective analysis of data from a prospectively identified cohort of AIS patients collected at a single large tertiary care center. Consecutive AIS patients admitted between January 2003 and December 2006 (n = 2148) were identified by screening hospital admission logs. Patients who received IV tPA within 3 hours of stroke onset (started either at our center or transferred to us after receiving tPA) or intra-arterial thrombolysis (IAT) or mechanical clot retrieval were included

Results

Of the 2148 AIS patients in this study, 308 (14.3%) were treated with thrombolytic therapy. Of these 308 patients, 210 (68%) received IV tPA without IAT, 41 (13%) eceived IV tPA plus IAT, and 57 (18%) received IAT only. Forty-four patients (14%) had either CM (n = 18) or RM (n = 26). Of these 44 malignancies, breast (n = 9; 21%) and lung (n = 9; 21%) were the most common, followed by colon (n = 8; 18%), hematologic (n = 5; 11%), prostate (n = 4; 9%), skin (n = 4; 9%), and all other types (n = 5; 11%).

Among the

Discussion

In this study, we found an association between CM and increased in-hospital mortality after thrombolytic therapy for AIS in univariate analysis, but this association did not persist when adjusting for other known factors associated with mortality. The mortality in AIS patients with CM did not appear to be due to increased rates of symptomatic ICH or other manifestations of hemostatic dysfunction, but rather was linked to withdrawal of care due to comorbid medical conditions (including the

References (20)

There are more references available in the full text version of this article.

Cited by (48)

  • Temporal Trends in the Use of Acute Recanalization Therapies for Ischemic Stroke in Patients with Cancer

    2019, Journal of Stroke and Cerebrovascular Diseases
    Citation Excerpt :

    Several retrospective studies have evaluated IV-tPA and EVT use in cancer patients with AIS. These analyses concentrated on the risk of hemorrhagic complications and death, and most were small, single-center case series that lacked control groups.19–21,30,31 These studies suggested that careful use of acute recanalization therapies in select cancer patients with AIS might be safe, as hemorrhage rates were similar to those from large randomized trials of predominantly noncancer AIS patients.3,32

  • Outcomes of fibrinolytic therapy for patients with metastatic cancer and acute pulmonary embolism

    2019, Pulmonary Pharmacology and Therapeutics
    Citation Excerpt :

    Hemorrhage in the setting of FT among those with metastatic cancer and PE has not been explored as of now, but our matched cohorts showed no significant difference in overall or intracranial hemorrhage risk. Similarly, low rates of hemorrhage have been seen among stroke patients with malignancy who received FT. Patients had higher mortality, particularly in the metastatic cancer arm, but risk of both ICH and all hemorrhage was no different between malignancy types and compared to those without cancer [14,15]. Other outcomes from FT use have been less well-documented in current literature of PE treatment.

View all citing articles on Scopus

The authors have no conflicts of interest to disclose.

View full text